product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Canine IL-4 Protein, CF
catalog :
754-CL-025/CF
quantity :
25 ug
price :
417 USD
more info or order :
R&D Systems product webpage
citations: 20
Reference
Pelst M, H xf6 bart C, de Rooster H, Devriendt B, Cox E. Immortalised canine buccal epithelial cells' CXCL8 secretion is affected by allergen extracts, Toll-like receptor ligands, IL-17A and calcitriol. Vet Res. 2022;53:72 pubmed publisher
Santos C, Costa S, Souza F, Mendes J, de Pinheiro C, Moreira D, et al. Blocking IL-10 signaling with soluble IL-10 receptor restores in vitro specific lymphoproliferative response in dogs with leishmaniasis caused by Leishmania infantum. PLoS ONE. 2021;16:e0239171 pubmed publisher
Stranahan L, Chaki S, Garcia Gonzalez D, Khalaf O, Arenas Gamboa A. Evaluation of the Efficacy of the Brucella canis RM6/66 ΔvjbR Vaccine Candidate for Protection against B. canis Infection in Mice. mSphere. 2020;5: pubmed publisher
Milhau N, Almouazen E, Bouteille S, Hellel Bourtal I, Azzouz Maache S, Benavides U, et al. In vitro evaluations on canine monocyte-derived dendritic cells of a nanoparticles delivery system for vaccine antigen against Echinococcus granulosus. PLoS ONE. 2020;15:e0229121 pubmed publisher
van Helvoort E, Popov Celeketić J, Eijkelkamp N, Coeleveld K, Tryfonidou M, Wijne C, et al. Canine IL4-10 fusion protein provides disease modifying activity in a canine model of OA; an exploratory study. PLoS ONE. 2019;14:e0219587 pubmed publisher
Thalmensi J, Pliquet E, Liard C, Chamel G, Kreuz C, Bestetti T, et al. A DNA telomerase vaccine for canine cancer immunotherapy. Oncotarget. 2019;10:3361-3372 pubmed publisher
Pujol M, Borie C, Montoya M, Ferreira A, Vernal R. Brucella canis induces canine CD4+ T cells multi-cytokine Th1/Th17 production via dendritic cell activation. Comp Immunol Microbiol Infect Dis. 2019;62:68-75 pubmed publisher
Konduri V, Halpert M, Baig Y, Coronado R, Rodgers J, Levitt J, et al. Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma. Cancer Gene Ther. 2019;: pubmed publisher
Hernández Granados A, Franco Molina M, Coronado Cerda E, Zapata Benavides P, Gamboa E, Ramos Zayas Y, et al. Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy. Res Vet Sci. 2018;121:23-30 pubmed publisher
Heinrich F, Lehmbecker A, Raddatz B, Kegler K, Tipold A, Stein V, et al. Morphologic, phenotypic, and transcriptomic characterization of classically and alternatively activated canine blood-derived macrophages in vitro. PLoS ONE. 2017;12:e0183572 pubmed publisher
Resende L, Aguiar Soares R, Gama Ker H, Roatt B, Mendonça L, Alves M, et al. Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge. PLoS ONE. 2016;11:e0161169 pubmed publisher
Petitdidier E, Pagniez J, Papierok G, Vincendeau P, Lemesre J, Bras Gonçalves R. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs. PLoS Negl Trop Dis. 2016;10:e0004614 pubmed publisher
Costa Pereira C, Moreira M, Soares R, Marteleto B, Ribeiro V, França Dias M, et al. One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis. BMC Vet Res. 2015;11:92 pubmed publisher
Qeska V, Barthel Y, Herder V, Stein V, Tipold A, Urhausen C, et al. Canine distemper virus infection leads to an inhibitory phenotype of monocyte-derived dendritic cells in vitro with reduced expression of co-stimulatory molecules and increased interleukin-10 transcription. PLoS ONE. 2014;9:e96121 pubmed publisher
Xiong W, Candolfi M, Liu C, Muhammad A, Yagiz K, Puntel M, et al. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS ONE. 2010;5:e11074 pubmed publisher
Lange S, Altmann S, Brandt B, Adam C, Riebau F, Vogel H, et al. Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model. Exp Hematol. 2009;37:143-50 pubmed publisher
Mason N, Coughlin C, Overley B, Cohen J, Mitchell E, Colligon T, et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther. 2008;15:955-65 pubmed publisher
Lemesre J, Holzmuller P, Gonçalves R, Bourdoiseau G, Hugnet C, Cavaleyra M, et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine. 2007;25:4223-34 pubmed
Fujiwara R, Loukas A, Mendez S, Williamson A, Bueno L, Wang Y, et al. Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs. Vaccine. 2006;24:501-9 pubmed
Lemesre J, Holzmuller P, Cavaleyra M, Gonçalves R, Hottin G, Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine. 2005;23:2825-40 pubmed
product information
brand :
R&D Systems
master code :
754-CL/CF
SKU :
754-CL-025/CF
product name :
Recombinant Canine IL-4 Protein, CF
description :
The Recombinant Canine IL-4 Protein, CF from R&D Systems is derived from E. coli. The Recombinant Canine IL-4 Protein, CF has been validated for the following applications: Bioactivity.
target :
IL-4
category :
Proteins and Enzymes
unit sizes :
25 ug
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS.
conjugate :
Unconjugated
purity :
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
species :
Canine
theoretical molecular weight :
12.9 kDa
gene symbol :
IL4
details of functionality :
Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. Kitamura, T. et al . (1989) J. Cell Physiol. 140 :323. The ED50 for this effect is 3-18 ng/mL.
endotoxin note :
<0.10 EU per 1 µg of the protein by the LAL method.
accessionNumbers :
AAD11563
applications :
Bioactivity
source :
E. coli-derived Recombinant Canine IL-4 Protein, CF
USD :
417 USD
alt names :
B cell growth factor 1, BCDF, B-cell stimulatory factor 1, BCGF1, BCGF-1, binetrakin, BSF1, BSF-1, IL4, IL-4B_cell stimulatory factor 1, IL4E12, interleukin 4, interleukin-4, Lymphocyte stimulatory factor 1, MGC79402, Pitrakinra
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.